Tips for pharma on getting ready for Brexit

25 October 2019
brexit_pills_large-1--1

When Brexit will happen, and whether it will involve the UK leaving with or without a deal, is not something that anyone can tell companies, but the government is at least making efforts to help them prepare for every eventuality.

The Department for Business, Energy and Industrial Strategy has issued a series of tips for the life science sector, which it has said is about ‘supporting business to get ready for Brexit and enabling them to advantage of the opportunities that leaving the European Union (EU) will bring’.

'Business preparedness is mixed'

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical